Bio-Techne is a biotechnology business based in the US. Bio-Techne shares (TECH) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $66.37 – a decrease of 12.59% over the previous week. Bio-Techne employs 3,100 staff and has a trailing 12-month revenue of around $1.2 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $66.37 |
|---|---|
| 52-week range | $60.85 - $85.39 |
| 50-day moving average | $74.31 |
| 200-day moving average | $73.62 |
| Wall St. target price | $85.25 |
| PE ratio | 79.7143 |
| Dividend yield | $0.32 (0.42%) |
| Earnings per share (TTM) | $0.91 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $66.86 from 2024-11-18
| 1 week (2024-11-14) | -7.83% |
|---|---|
| 1 month (2024-10-21) | -4.97% |
| 3 months (2024-08-20) | -7.58% |
| 6 months (2024-05-21) | -19.13% |
| 1 year (2023-11-21) | 5.26% |
|---|---|
| 2 years (2022-11-21) | -18.76% |
| 3 years (2021-11-19) | 123.3813 |
| 5 years (2019-11-21) | 27.60% |
Valuing Bio-Techne stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bio-Techne's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Bio-Techne's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 80x. In other words, Bio-Techne shares trade at around 80x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Bio-Techne's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.7891. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bio-Techne's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Bio-Techne's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $308.5 million.
The EBITDA is a measure of a Bio-Techne's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $1.2 billion |
|---|---|
| Operating margin TTM | 18.15% |
| Gross profit TTM | $770.2 million |
| Return on assets TTM | 5.55% |
| Return on equity TTM | 7.29% |
| Profit margin | 12.86% |
| Book value | $13.46 |
| Market Capitalization | $11.5 billion |
TTM: trailing 12 months
Dividend payout ratio: 17.88% of net profits
Recently Bio-Techne has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Bio-Techne shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Bio-Techne's case, that would currently equate to about $0.32 per share.
While Bio-Techne's payout ratio might seem low, this can signify that Bio-Techne is investing more in its future growth.
Bio-Techne's most recent dividend payout was on 21 November 2024. The latest dividend was paid out to all shareholders who bought their shares by 7 November 2024 (the "ex-dividend date").
Bio-Techne's shares were split on a 4:1 basis on 29 November 2022 . So if you had owned 1 share the day before before the split, the next day you'd have owned 4 shares. This wouldn't directly have changed the overall worth of your Bio-Techne shares – just the quantity. However, indirectly, the new 75% lower share price could have impacted the market appetite for Bio-Techne shares which in turn could have impacted Bio-Techne's share price.
Over the last 12 months, Bio-Techne's shares have ranged in value from as little as $60.8476 up to $85.3886. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bio-Techne's is 1.278. This would suggest that Bio-Techne's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.